Navigation Links
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Date:3/13/2009

ror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 10-Q and 10-KSB. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a r
'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
2. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
4. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
5. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
6. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
7. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
8. Eiger BioPharmaceuticals Raises $7.1 Million A Round
9. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
10. Mach One Closes on Acquisition of Biopharmaceutical Design & Engineering Firm
11. TechniKroms Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... 20, 2014 HealthTronics, Inc. ... interventional radiology products and services, has signed a ... Clinicon Corporation for its high precision ... of minimally invasive, mobile, surgical technology—offering more choices ... the agreement, HealthTronics will make available Clinicon’s FDA-cleared ...
(Date:9/19/2014)... From crop yields to disease risks, the biological characteristics ... traits." Just as for heightthe textbook example of a ... are shaped by multiple genetic and environmental influences, making ... down such genes, geneticists typically mate two individuals that ... a small mouseand then study their descendents, looking for ...
(Date:9/19/2014)... Follow us on LinkedIn ... the world has attracted diverse players including academic ... The early years of nanotechnology development was dominated ... the high risks involved, which deterred private and ... evolving technology have been growing over the years, ...
(Date:9/19/2014)... 2014  Nektar Therapeutics (NASDAQ: NKTR ... the analgesic profiles of a series of the ... molecules. The preclinical research candidates were created using ... The analgesic properties of kappa receptor agonism ... Kappa opioid receptors are expressed in the ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... Inc., a privately held company developing and commercializing novel ... for new and existing therapeutics, announced today that Edward ... presenting at the Annual UBS Global Life Sciences Conference ... City on Tuesday, September 20, 2011 at 12:30 p.m. ...
... , Chemosaturation Demonstrates Clinically Meaningful Tumor ... Delcath Systems, Inc. (NASDAQ: DCTH ... tumor (mNET) cohort of the Company,s recently completed Phase ... and Interventional Radiological Society of Europe (CIRSE) congress ...
... to be installed at the Rensselaer Polytechnic Institute ... across the nation and boost the university,s international ... high-performance computing, and web science. Funded ... Science Foundation (NSF) and with additional support from ...
Cached Biology Technology:Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City 2Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 2Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 3Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 4Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 5New supercomputer to boost Rensselaer leadership in high-performance computing 2New supercomputer to boost Rensselaer leadership in high-performance computing 3New supercomputer to boost Rensselaer leadership in high-performance computing 4
(Date:9/19/2014)... -- Nxt-ID, Inc. (Nasdaq: NXTD and NXTDW) ("Nxt-ID" ... m-commerce market, updates the "Wocket in Your Pocket" celebrity ad campaign, ... middleweight weight classes, Vinny Pazienza (PAZ). ... of Thrones actor Ciaran Hinds and Sons ... Katey Sagal have been cast in Bleed for This ...
(Date:9/18/2014)... in the primitive brainstem has revealed how we fall ... of Medicine and the University at Buffalo School of ... "sleep node" identified in the mammalian brain whose activity ... deep sleep. , Published online in August in ... of all of the brain,s sleep-promoting activity originates from ...
(Date:9/18/2014)... A team of researchers from McGill University and ... form of polyethylene ,microbeads, Canadian Journal of ... likely originate from cosmetics, household cleansers, or industrial ... abrasives. Owing to their small size and buoyancy, ... Microplastics are a global contaminant in the ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2Microplastic pollution discovered in St. Lawrence River sediments 2
... at SUNY Downstate Medical Center,s School of Public Health ... and environmental sources of exposure to mercury. The research, ... factors that may be associated with elevated mercury levels, ... study, published this month in the Journal of ...
... Madison, Wisconsin -- It,s the vicious cycle of funding-- ... The drop leads to declines in faculty and ... to a shortage of qualified graduates. "Obviously if ... have the support staff or the operating budget. ...
... in German . , T-cells are the immune ... the body and put them out of action. Their precursors are ... thymus. Here, they mature and differentiate to perform a variety of ... in Freiburg have now succeeded for the first time in observing ...
Cached Biology News:Study finds Caribbean-American women at higher risk for elevated mercury levels 2Study finds Caribbean-American women at higher risk for elevated mercury levels 3Study finds Caribbean-American women at higher risk for elevated mercury levels 4Live from the thymus: T-cells on the move 2Live from the thymus: T-cells on the move 3
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... PRO S-7 stirrers deliver accurate ... channels fluids away from internal ... easy-to-use controls which allow users ... ceramic tops feature a chemical ...
... Agencourt AMPure is a magnetic ... requires no sample transfer, centrifugation ... purifies small and large PCR ... 384-well microplates. Agencourt AMPure can ...
... These 1.5L PYREX trypsinizing ... homogenous tissue samples into cell ... proteins. Heavy beaded neck accepts ... enhance vigorous agitation. • Height ...
Biology Products: